written on 04.04.2014

British cost watchdog backtracks again on Roche's Tarceva


After intitially recommending Roche's targeted cancer drug Tarceva for use by Britain's National Health Service, the U.K.'s National Institute for Health and Care Excellence said in February it was reviewing the recommendation. Now, it looks likely to revert back to its original stance–a reversal of fortune the Swiss drugmaker is pleased with.